2 ‘Strong Buy' Stocks That Wall Street Believes Can Soar 360% to 780% [Yahoo! Finance]
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: Yahoo! Finance
For long-term biotech investors who can accept the risk of clinical-stage drugmakers, Eledon (ELDN) and Acumen (ABOS) are exciting opportunities to look at. However, given that they are penny stocks, they might be suitable for investors with a high-risk appetite. Eledon Pharmaceuticals (ELDN) Eledon Pharmaceuticals is a clinical-stage biotech company focused on immunology, particularly immunomodulation for transplantation (organs and cells), with some work in autoimmune and neurodegenerative diseases. The company's inclusion in the Russell 3000 and Russell 2000 indices in June increased its visibility at a time when Eledon is approaching multiple clinical catalysts. More News from Barchart Dear Amazon Stock Fans, Mark Your Calendars for October 7 Apple CEO Tim Cook Just Revealed 1 Little-Known Tech Stock for Investors to Snatch Up Here SoFi Stock Is Exploding Higher, But Don't Cash Out Yet Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals (NASDAQ:ELDN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare ConferenceGlobeNewswire
- Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineGlobeNewswire
- Eledon Pharmaceuticals (NASDAQ:ELDN) had its price target lowered by analysts at Guggenheim from $9.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
ELDN
Earnings
- 11/14/25 - Beat
ELDN
Sec Filings
- 11/24/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- 11/14/25 - Form 10-Q
- ELDN's page on the SEC website